adMare Accelerate Program for Quebec emerging companies
adMare BioInnovations, Canada’s global life sciences venture, is proud to welcome six start-ups selected to join its acceleration program for Quebec emerging companies. The Accelerate Program is designed to address a fundamental pillar of adMare's Mission: to support the scale-up of promising life sciences companies, and help them grow into new anchors for the industry.
Thanks to contributions from the Government of Quebec, through Start-Up Quebec funding from the Ministère de l'Économie et de l'Innovation, and the City of Montreal, the selected companies will benefit from $150,000 in customized access to adMare resources, such as laboratories and offices at reduced rates, scientific and business support, and training. With the support of our strategic partners BIOQuébec and Montréal InVivo, the participants will also access unique networking and mentoring opportunities, and increase their visibility in Quebec’s life sciences community.
The selected companies are:
Cura Therapeutics is developing innovative immunotherapies to cure cancer and infectious diseases. Their technologies harness cytokines to create multi-functional proteins with potent anti-cancer and antiviral properties.
In Vivo AI is an interdisciplinary team of scientists and engineers out of Mila - Quebec AI institute developing new machine learning technologies for molecular design and optimization.
Modelis is accelerating drug discovery for rare genetic diseases.
Molecular Forecaster is a reliable, self-sustaining computational chemistry service provider, developing its own software for application in various drug discovery campaigns.
Targa Biomedical is developing novel therapeutics to reverse the structural deterioration associated with degenerative disc and articular joint diseases, such as osteoarthritis, and to reduce the associated pain and inflammation.
Trepso Therapeutics is developing novel therapeutics to reverse the structural deterioration associated with degenerative disc and articular joint diseases, such as osteoarthritis, and to reduce the associated pain and inflammation.
With the support of :
For additional information, please contact:
Lydiane Gaborieau, PhD
Scientific and Business Affairs Administrator
adMare BioInnovations
514.583.9334
lgaborieau@admarebio.com
